Share Price and Basic Stock Data
Last Updated: December 24, 2025, 12:55 pm
| PEG Ratio | 11.84 |
|---|
Analyst Insight & Comprehensive Analysis
AI Stock Ranker – Real-Time Fundamental Strength Score
Business Overview and Revenue Trends
Jubilant Pharmova Ltd operates in the pharmaceuticals industry, reporting a current market capitalization of ₹17,214 Cr and a share price of ₹1,081. The company has shown resilience in its revenue generation, with total sales rising from ₹6,130 Cr in FY 2022 to ₹7,234 Cr in FY 2025, reflecting a compound annual growth rate (CAGR) of approximately 8.4%. Quarterly sales figures indicate a positive trend, with the latest quarter (June 2025) recording sales of ₹1,901 Cr, compared to ₹1,678 Cr in March 2023. This upward trajectory suggests effective management and a robust product pipeline. Notably, the operating profit margin (OPM) has improved, standing at 16% for FY 2025, compared to 12% in FY 2023, signaling enhanced operational efficiency. Overall, the revenue growth positions Jubilant Pharmova favorably within the competitive pharmaceuticals sector in India.
Profitability and Efficiency Metrics
Jubilant Pharmova’s profitability metrics reveal a mixed performance landscape. The net profit for FY 2025 stood at ₹836 Cr, a substantial recovery from a loss of ₹65 Cr in FY 2023. This rebound was supported by a notable increase in earnings per share (EPS), which rose to ₹52.99 in FY 2025 from a negative ₹3.83 in FY 2023. The company also recorded an interest coverage ratio (ICR) of 5.12x, indicating its ability to meet interest obligations comfortably. However, the return on equity (ROE) remains modest at 9.55%, which is relatively low compared to industry peers, suggesting room for improvement in capital efficiency. Additionally, the cash conversion cycle (CCC) has improved to 65 days, reflecting better management of working capital. Overall, while profitability has improved, enhancing ROE and maintaining cost control will be crucial for sustaining growth.
Balance Sheet Strength and Financial Ratios
Jubilant Pharmova’s balance sheet exhibits a strong foundation, with total assets reaching ₹12,584 Cr as of FY 2025, supported by total liabilities of ₹12,584 Cr and equity capital of ₹16 Cr. The company’s reserves have increased significantly, standing at ₹6,576 Cr, indicating a strong retained earnings position. Borrowings have reduced to ₹2,883 Cr from ₹3,677 Cr in FY 2023, contributing to a lower total debt to equity ratio of 0.38x, which is favorable compared to industry norms. The price-to-book value (P/BV) ratio stood at 2.25x, reflecting investor confidence in the company’s growth prospects. Furthermore, the current ratio is healthy at 1.65, suggesting adequate liquidity to cover short-term obligations. This solid financial position allows Jubilant Pharmova to invest in growth opportunities and navigate potential economic challenges effectively.
Shareholding Pattern and Investor Confidence
The shareholding pattern of Jubilant Pharmova indicates a diverse ownership structure, with promoters holding 47.67% of the equity, while foreign institutional investors (FIIs) and domestic institutional investors (DIIs) hold 16.56% and 10.53%, respectively. The public ownership stands at 24.60%, reflecting a balanced distribution that can enhance governance and accountability. The decline in promoter holding from 50.67% to 47.67% over recent quarters may raise concerns about management’s control, but it also opens avenues for institutional investment. The number of shareholders has fluctuated, with a current count of 93,336, indicating sustained interest among retail investors. Overall, the diverse shareholding structure is likely to foster investor confidence in the company’s strategic direction and governance.
Outlook, Risks, and Final Insight
Looking ahead, Jubilant Pharmova’s outlook appears cautiously optimistic, bolstered by its improving profitability and solid financial metrics. However, risks remain, including potential regulatory challenges and market competition, which could impact growth. The company’s ability to innovate and expand its product offerings will be critical in sustaining its revenue growth. Additionally, fluctuations in raw material costs may affect margins, necessitating effective cost management strategies. Should the company successfully navigate these challenges, it could enhance shareholder value and improve its market position. Conversely, failure to address these risks could hinder growth and profitability. Therefore, maintaining operational efficiency and fostering innovation will be essential for Jubilant Pharmova to achieve its long-term objectives.
Source: Getaka Fundamental Analysis | Generated using proprietary financial data.
Competitors
| Stock Name ⇩ | Market Cap ⇩ | Current Price ⇩ | High / Low ⇩ | Stock P/E ⇩ | Book Value ⇩ | Dividend Yield ⇩ | ROCE ⇩ | ROE ⇩ | Face Value ⇩ |
|---|---|---|---|---|---|---|---|---|---|
| Lactose (India) Ltd | 138 Cr. | 110 | 231/84.3 | 30.5 | 49.6 | 0.00 % | 12.9 % | 9.69 % | 10.0 |
| MPS Pharmaa Ltd | 3.54 Cr. | 1.85 | 4.29/1.76 | 0.33 | 0.00 % | 9.79 % | 59.0 % | 10.0 | |
| Gujarat Themis Biosyn Ltd | 4,446 Cr. | 408 | 479/192 | 92.1 | 24.3 | 0.16 % | 27.3 % | 21.7 % | 1.00 |
| Gujarat Terce Laboratories Ltd | 35.2 Cr. | 47.5 | 88.6/37.2 | 10.6 | 0.00 % | 41.4 % | 14.6 % | 10.0 | |
| Gujarat Inject (Kerala) Ltd | 49.8 Cr. | 34.0 | 34.7/17.0 | 119 | 6.93 | 0.00 % | 13.5 % | 11.0 % | 10.0 |
| Industry Average | 20,196.60 Cr | 1,152.36 | 53.08 | 202.18 | 0.35% | 16.29% | 15.20% | 6.10 |
Quarterly Result
| Metric | Jun 2022 | Sep 2022 | Dec 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 1,452 | 1,600 | 1,552 | 1,678 | 1,587 | 1,680 | 1,677 | 1,759 | 1,732 | 1,752 | 1,822 | 1,929 | 1,901 |
| Expenses | 1,259 | 1,384 | 1,408 | 1,459 | 1,419 | 1,438 | 1,459 | 1,487 | 1,480 | 1,463 | 1,535 | 1,584 | 1,611 |
| Operating Profit | 192 | 216 | 144 | 219 | 168 | 242 | 218 | 271 | 252 | 289 | 287 | 345 | 290 |
| OPM % | 13% | 14% | 9% | 13% | 11% | 14% | 13% | 15% | 15% | 17% | 16% | 18% | 15% |
| Other Income | 11 | -44 | 10 | 21 | 9 | 19 | 49 | -151 | 410 | 8 | -10 | 9 | 12 |
| Interest | 40 | 42 | 51 | 56 | 62 | 66 | 71 | 73 | 71 | 61 | 56 | 53 | 49 |
| Depreciation | 95 | 94 | 94 | 271 | 90 | 97 | 95 | 101 | 91 | 91 | 91 | 95 | 98 |
| Profit before tax | 69 | 36 | 9 | -86 | 25 | 98 | 101 | -54 | 500 | 144 | 130 | 206 | 154 |
| Tax % | 32% | 87% | 285% | 16% | 76% | 37% | 34% | 15% | 4% | 29% | 23% | 27% | 34% |
| Net Profit | 47 | 5 | -16 | -100 | 6 | 62 | 66 | -62 | 482 | 102 | 101 | 151 | 102 |
| EPS in Rs | 2.96 | 0.34 | -0.98 | -6.15 | 0.40 | 3.92 | 4.19 | -3.68 | 30.26 | 6.45 | 6.33 | 9.64 | 6.46 |
Last Updated: August 1, 2025, 6:40 pm
Below is a detailed analysis of the quarterly data for Jubilant Pharmova Ltd based on the most recent figures (Jun 2025) and their trends compared to the previous period:
- For Sales, as of Jun 2025, the value is 1,901.00 Cr.. The value appears to be declining and may need further review. It has decreased from 1,929.00 Cr. (Mar 2025) to 1,901.00 Cr., marking a decrease of 28.00 Cr..
- For Expenses, as of Jun 2025, the value is 1,611.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 1,584.00 Cr. (Mar 2025) to 1,611.00 Cr., marking an increase of 27.00 Cr..
- For Operating Profit, as of Jun 2025, the value is 290.00 Cr.. The value appears to be declining and may need further review. It has decreased from 345.00 Cr. (Mar 2025) to 290.00 Cr., marking a decrease of 55.00 Cr..
- For OPM %, as of Jun 2025, the value is 15.00%. The value appears to be declining and may need further review. It has decreased from 18.00% (Mar 2025) to 15.00%, marking a decrease of 3.00%.
- For Other Income, as of Jun 2025, the value is 12.00 Cr.. The value appears strong and on an upward trend. It has increased from 9.00 Cr. (Mar 2025) to 12.00 Cr., marking an increase of 3.00 Cr..
- For Interest, as of Jun 2025, the value is 49.00 Cr.. The value appears to be improving (decreasing) as expected. It has decreased from 53.00 Cr. (Mar 2025) to 49.00 Cr., marking a decrease of 4.00 Cr..
- For Depreciation, as of Jun 2025, the value is 98.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 95.00 Cr. (Mar 2025) to 98.00 Cr., marking an increase of 3.00 Cr..
- For Profit before tax, as of Jun 2025, the value is 154.00 Cr.. The value appears to be declining and may need further review. It has decreased from 206.00 Cr. (Mar 2025) to 154.00 Cr., marking a decrease of 52.00 Cr..
- For Tax %, as of Jun 2025, the value is 34.00%. The value appears to be increasing, which may not be favorable. It has increased from 27.00% (Mar 2025) to 34.00%, marking an increase of 7.00%.
- For Net Profit, as of Jun 2025, the value is 102.00 Cr.. The value appears to be declining and may need further review. It has decreased from 151.00 Cr. (Mar 2025) to 102.00 Cr., marking a decrease of 49.00 Cr..
- For EPS in Rs, as of Jun 2025, the value is 6.46. The value appears to be declining and may need further review. It has decreased from 9.64 (Mar 2025) to 6.46, marking a decrease of 3.18.
Overall, while many items appear to show a positive trend, any significant downward movement warrant further investigation.
Profit & Loss - Annual Report
Last Updated: December 15, 2025, 5:07 am
| Metric | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 5,762 | 5,751 | 5,749 | 5,861 | 7,518 | 9,111 | 5,976 | 6,099 | 6,130 | 6,282 | 6,703 | 7,234 | 7,618 |
| Expenses | 4,763 | 5,141 | 4,493 | 4,510 | 5,995 | 7,367 | 4,428 | 4,695 | 4,980 | 5,503 | 5,802 | 6,061 | 6,354 |
| Operating Profit | 999 | 610 | 1,256 | 1,352 | 1,522 | 1,744 | 1,548 | 1,403 | 1,150 | 779 | 901 | 1,173 | 1,263 |
| OPM % | 17% | 11% | 22% | 23% | 20% | 19% | 26% | 23% | 19% | 12% | 13% | 16% | 17% |
| Other Income | -173 | 86 | 4 | 19 | 36 | -249 | 225 | 263 | 8 | -9 | -76 | 416 | 15 |
| Interest | 337 | 368 | 371 | 341 | 284 | 220 | 200 | 184 | 145 | 188 | 272 | 240 | 208 |
| Depreciation | 281 | 288 | 347 | 291 | 415 | 371 | 340 | 349 | 382 | 554 | 382 | 369 | 389 |
| Profit before tax | 207 | 40 | 542 | 738 | 859 | 904 | 1,233 | 1,133 | 630 | 28 | 170 | 981 | 681 |
| Tax % | 34% | 200% | 29% | 22% | 26% | 36% | 27% | 26% | 34% | 333% | 57% | 15% | |
| Net Profit | 138 | -40 | 387 | 575 | 634 | 577 | 898 | 836 | 413 | -65 | 73 | 836 | 474 |
| EPS in Rs | 6.84 | -3.63 | 24.60 | 36.14 | 40.35 | 36.06 | 56.39 | 52.47 | 25.98 | -3.83 | 4.84 | 52.69 | 29.98 |
| Dividend Payout % | 43% | -83% | 12% | 8% | 7% | 12% | 9% | 10% | 19% | -130% | 102% | 9% |
YoY Net Profit Growth
| Year | 2014-2015 | 2015-2016 | 2016-2017 | 2017-2018 | 2018-2019 | 2019-2020 | 2020-2021 | 2021-2022 | 2022-2023 | 2023-2024 | 2024-2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| YoY Net Profit Growth (%) | -128.99% | 1067.50% | 48.58% | 10.26% | -8.99% | 55.63% | -6.90% | -50.60% | -115.74% | 212.31% | 1045.21% |
| Change in YoY Net Profit Growth (%) | 0.00% | 1196.49% | -1018.92% | -38.32% | -19.25% | 64.62% | -62.54% | -43.69% | -65.14% | 328.05% | 832.90% |
Jubilant Pharmova Ltd has shown an inconsistent trend in YoY Net Profit Growth (%) in the last 11 years from 2014-2015 to 2024-2025.
Growth
| Compounded Sales Growth | |
|---|---|
| 10 Years: | 2% |
| 5 Years: | 4% |
| 3 Years: | 6% |
| TTM: | 8% |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | 24% |
| 5 Years: | -10% |
| 3 Years: | 10% |
| TTM: | 107% |
| Stock Price CAGR | |
|---|---|
| 10 Years: | 15% |
| 5 Years: | 8% |
| 3 Years: | 48% |
| 1 Year: | 14% |
| Return on Equity | |
|---|---|
| 10 Years: | 10% |
| 5 Years: | 6% |
| 3 Years: | 1% |
| Last Year: | 10% |
Last Updated: September 5, 2025, 8:35 am
Balance Sheet
Last Updated: December 4, 2025, 1:30 am
| Month | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Sep 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Equity Capital | 15 | 16 | 16 | 16 | 16 | 16 | 16 | 16 | 16 | 16 | 16 | 16 | 16 |
| Reserves | 2,611 | 2,438 | 2,951 | 3,420 | 4,071 | 4,793 | 5,588 | 4,726 | 5,303 | 5,383 | 5,418 | 6,239 | 6,576 |
| Borrowings | 4,395 | 4,793 | 4,493 | 4,045 | 3,469 | 4,840 | 4,808 | 2,830 | 3,192 | 3,677 | 3,664 | 2,731 | 2,883 |
| Other Liabilities | 1,842 | 1,372 | 1,280 | 1,417 | 1,902 | 1,670 | 1,898 | 1,192 | 1,319 | 1,853 | 2,240 | 3,598 | 4,047 |
| Total Liabilities | 8,864 | 8,619 | 8,740 | 8,899 | 9,457 | 11,319 | 12,310 | 8,763 | 9,830 | 10,929 | 11,338 | 12,584 | 13,521 |
| Fixed Assets | 5,099 | 4,911 | 5,104 | 5,107 | 5,401 | 5,648 | 6,340 | 4,609 | 4,871 | 5,183 | 5,091 | 5,176 | 7,354 |
| CWIP | 472 | 597 | 611 | 684 | 671 | 901 | 768 | 897 | 1,090 | 1,562 | 2,103 | 3,630 | 2,344 |
| Investments | 34 | 40 | 85 | 103 | 124 | 115 | 69 | 241 | 239 | 256 | 42 | 44 | 45 |
| Other Assets | 3,259 | 3,071 | 2,939 | 3,006 | 3,262 | 4,654 | 5,133 | 3,017 | 3,631 | 3,928 | 4,101 | 3,735 | 3,778 |
| Total Assets | 8,864 | 8,619 | 8,740 | 8,899 | 9,457 | 11,319 | 12,310 | 8,763 | 9,830 | 10,929 | 11,338 | 12,584 | 13,521 |
Below is a detailed analysis of the balance sheet data for Jubilant Pharmova Ltd based on the most recent figures (Sep 2025) and their trends compared to the previous period:
- For Equity Capital, as of Sep 2025, the value is 16.00 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2025) which recorded 16.00 Cr..
- For Reserves, as of Sep 2025, the value is 6,576.00 Cr.. The value appears strong and on an upward trend. It has increased from 6,239.00 Cr. (Mar 2025) to 6,576.00 Cr., marking an increase of 337.00 Cr..
- For Borrowings, as of Sep 2025, the value is 2,883.00 Cr.. The value appears to be increasing, which may not be favorable. Additionally, since Reserves exceed Borrowings, this is considered a positive sign. It has increased from 2,731.00 Cr. (Mar 2025) to 2,883.00 Cr., marking an increase of 152.00 Cr..
- For Other Liabilities, as of Sep 2025, the value is 4,047.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 3,598.00 Cr. (Mar 2025) to 4,047.00 Cr., marking an increase of 449.00 Cr..
- For Total Liabilities, as of Sep 2025, the value is 13,521.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 12,584.00 Cr. (Mar 2025) to 13,521.00 Cr., marking an increase of 937.00 Cr..
- For Fixed Assets, as of Sep 2025, the value is 7,354.00 Cr.. The value appears strong and on an upward trend. It has increased from 5,176.00 Cr. (Mar 2025) to 7,354.00 Cr., marking an increase of 2,178.00 Cr..
- For CWIP, as of Sep 2025, the value is 2,344.00 Cr.. The value appears to be declining and may need further review. It has decreased from 3,630.00 Cr. (Mar 2025) to 2,344.00 Cr., marking a decrease of 1,286.00 Cr..
- For Investments, as of Sep 2025, the value is 45.00 Cr.. The value appears strong and on an upward trend. It has increased from 44.00 Cr. (Mar 2025) to 45.00 Cr., marking an increase of 1.00 Cr..
- For Other Assets, as of Sep 2025, the value is 3,778.00 Cr.. The value appears strong and on an upward trend. It has increased from 3,735.00 Cr. (Mar 2025) to 3,778.00 Cr., marking an increase of 43.00 Cr..
- For Total Assets, as of Sep 2025, the value is 13,521.00 Cr.. The value appears strong and on an upward trend. It has increased from 12,584.00 Cr. (Mar 2025) to 13,521.00 Cr., marking an increase of 937.00 Cr..
Notably, the Reserves (6,576.00 Cr.) exceed the Borrowings (2,883.00 Cr.), indicating a solid financial buffer.
Overall, while many items appear to show a positive trend, any significant downward movement or items where Borrowings exceed Reserves warrant further investigation.
Cash Flow
| Month | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
Free Cash Flow
| Month | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Free Cash Flow | 995.00 | 606.00 | -3.00 | -3.00 | -2.00 | -3.00 | -3.00 | -1.00 | -2.00 | 776.00 | 898.00 | -1.00 |
Free Cash Flow = Income Generated from Operational Activities - Borrowings - Capital Work in Progress (CWIP)
Consistent positive free cash flow is crucial for businesses as it indicates their ability to generate cash from their core operations. It provides financial flexibility, allowing companies to invest in growth opportunities, pay dividends to shareholders, reduce debt, and weather economic downturns more effectively.
Financial Efficiency Indicators
| Month | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debtor Days | 51 | 52 | 60 | 63 | 55 | 51 | 79 | 49 | 55 | 56 | 50 | 45 |
| Inventory Days | 200 | 169 | 207 | 223 | 177 | 147 | 463 | 268 | 308 | 268 | 220 | 178 |
| Days Payable | 107 | 99 | 106 | 137 | 145 | 106 | 273 | 124 | 139 | 160 | 146 | 158 |
| Cash Conversion Cycle | 144 | 122 | 162 | 149 | 87 | 92 | 268 | 194 | 224 | 165 | 124 | 65 |
| Working Capital Days | -92 | 12 | 4 | 50 | 45 | 45 | 62 | 74 | 56 | 57 | 56 | 16 |
| ROCE % | 11% | 6% | 13% | 15% | 15% | 16% | 15% | 12% | 10% | 3% | 7% | 10% |
Mutual Fund Holdings
| Fund Name | No of Shares | AUM (%) | Amount Invested (Cr) | Previous Number of Shares | Previous Date | Percentage Change |
|---|---|---|---|---|---|---|
| Quant Small Cap Fund | 2,947,185 | 1.06 | 321.15 | N/A | N/A | N/A |
| Kotak Multicap Fund | 1,842,613 | 0.9 | 200.79 | N/A | N/A | N/A |
| Bandhan Small Cap Fund | 1,812,233 | 1.09 | 197.48 | 1,742,233 | 2025-12-15 06:52:35 | 4.02% |
| Bandhan Focused Fund | 854,914 | 4.46 | 93.16 | 794,914 | 2025-12-15 04:27:23 | 7.55% |
| Kotak Contra Fund | 578,400 | 1.26 | 63.03 | N/A | N/A | N/A |
| Aditya Birla Sun Life Small Cap Fund | 476,931 | 1.03 | 51.97 | 417,834 | 2025-12-14 06:35:27 | 14.14% |
| Aditya Birla Sun Life Bal Bhavishya Yojna | 105,213 | 0.95 | 11.47 | N/A | N/A | N/A |
| Aditya Birla Sun Life Pharma & Healthcare Fund | 94,886 | 1.21 | 10.34 | N/A | N/A | N/A |
| UTI Healthcare Fund | 89,675 | 0.87 | 9.77 | N/A | N/A | N/A |
| Tata India Pharma & HealthCare Fund | 6,772 | 0.06 | 0.74 | N/A | N/A | N/A |
Key Financial Ratios
| Month | Mar 25 | Mar 24 | Mar 23 | Mar 22 | Mar 21 |
|---|---|---|---|---|---|
| FaceValue | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 |
| Basic EPS (Rs.) | 52.99 | 4.87 | -3.83 | 26.00 | 52.48 |
| Diluted EPS (Rs.) | 52.99 | 4.86 | -3.83 | 26.00 | 52.48 |
| Cash EPS (Rs.) | 76.29 | 27.25 | 29.98 | 50.55 | 73.70 |
| Book Value[Excl.RevalReserv]/Share (Rs.) | 395.88 | 343.11 | 338.91 | 333.97 | 297.85 |
| Book Value[Incl.RevalReserv]/Share (Rs.) | 395.88 | 343.11 | 338.91 | 333.97 | 297.85 |
| Revenue From Operations / Share (Rs.) | 457.88 | 424.23 | 394.85 | 385.08 | 383.10 |
| PBDIT / Share (Rs.) | 77.88 | 61.36 | 51.20 | 73.35 | 88.83 |
| PBIT / Share (Rs.) | 54.55 | 37.19 | 16.38 | 49.37 | 66.91 |
| PBT / Share (Rs.) | 62.09 | 9.27 | 0.97 | 40.23 | 54.01 |
| Net Profit / Share (Rs.) | 52.96 | 3.08 | -4.85 | 26.57 | 51.78 |
| NP After MI And SOA / Share (Rs.) | 53.13 | 4.88 | -3.83 | 26.00 | 52.51 |
| PBDIT Margin (%) | 17.00 | 14.46 | 12.96 | 19.04 | 23.18 |
| PBIT Margin (%) | 11.91 | 8.76 | 4.14 | 12.82 | 17.46 |
| PBT Margin (%) | 13.56 | 2.18 | 0.24 | 10.44 | 14.09 |
| Net Profit Margin (%) | 11.56 | 0.72 | -1.22 | 6.90 | 13.51 |
| NP After MI And SOA Margin (%) | 11.60 | 1.15 | -0.97 | 6.75 | 13.70 |
| Return on Networth / Equity (%) | 13.41 | 1.41 | -1.12 | 7.78 | 17.62 |
| Return on Capital Employeed (%) | 8.13 | 6.08 | 2.77 | 9.35 | 13.53 |
| Return On Assets (%) | 6.58 | 0.66 | -0.54 | 4.14 | 9.37 |
| Long Term Debt / Equity (X) | 0.34 | 0.58 | 0.57 | 0.46 | 0.54 |
| Total Debt / Equity (X) | 0.38 | 0.62 | 0.63 | 0.55 | 0.54 |
| Asset Turnover Ratio (%) | 0.59 | 0.59 | 0.59 | 0.01 | 0.37 |
| Current Ratio (X) | 1.65 | 2.05 | 2.12 | 2.20 | 2.81 |
| Quick Ratio (X) | 1.13 | 1.37 | 1.34 | 1.42 | 1.74 |
| Inventory Turnover Ratio (X) | 5.98 | 1.36 | 1.26 | 0.00 | 1.44 |
| Dividend Payout Ratio (NP) (%) | 9.48 | 103.24 | -130.60 | 19.23 | 0.00 |
| Dividend Payout Ratio (CP) (%) | 6.58 | 17.34 | 16.15 | 10.00 | 0.00 |
| Earning Retention Ratio (%) | 90.52 | -3.24 | 230.60 | 80.77 | 0.00 |
| Cash Earning Retention Ratio (%) | 93.42 | 82.66 | 83.85 | 90.00 | 0.00 |
| Interest Coverage Ratio (X) | 5.12 | 3.56 | 4.33 | 8.03 | 7.68 |
| Interest Coverage Ratio (Post Tax) (X) | 2.99 | 1.80 | 0.89 | 3.91 | 4.17 |
| Enterprise Value (Cr.) | 15436.46 | 11426.80 | 6827.69 | 8114.60 | 12743.97 |
| EV / Net Operating Revenue (X) | 2.13 | 1.70 | 1.09 | 1.32 | 2.09 |
| EV / EBITDA (X) | 12.54 | 11.79 | 8.38 | 6.95 | 9.01 |
| MarketCap / Net Operating Revenue (X) | 1.95 | 1.34 | 0.70 | 1.01 | 1.78 |
| Retention Ratios (%) | 90.51 | -3.24 | 230.60 | 80.76 | 0.00 |
| Price / BV (X) | 2.25 | 1.65 | 0.82 | 1.16 | 2.28 |
| Price / Net Operating Revenue (X) | 1.95 | 1.34 | 0.70 | 1.01 | 1.78 |
| EarningsYield | 0.05 | 0.01 | -0.01 | 0.06 | 0.07 |
After reviewing the key financial ratios for Jubilant Pharmova Ltd, here is a detailed analysis based on the latest available data and recent trends:
- For FaceValue, as of Mar 25, the value is 1.00. This value is within the healthy range. There is no change compared to the previous period (Mar 24) which recorded 1.00.
- For Basic EPS (Rs.), as of Mar 25, the value is 52.99. This value is within the healthy range. It has increased from 4.87 (Mar 24) to 52.99, marking an increase of 48.12.
- For Diluted EPS (Rs.), as of Mar 25, the value is 52.99. This value is within the healthy range. It has increased from 4.86 (Mar 24) to 52.99, marking an increase of 48.13.
- For Cash EPS (Rs.), as of Mar 25, the value is 76.29. This value is within the healthy range. It has increased from 27.25 (Mar 24) to 76.29, marking an increase of 49.04.
- For Book Value[Excl.RevalReserv]/Share (Rs.), as of Mar 25, the value is 395.88. It has increased from 343.11 (Mar 24) to 395.88, marking an increase of 52.77.
- For Book Value[Incl.RevalReserv]/Share (Rs.), as of Mar 25, the value is 395.88. It has increased from 343.11 (Mar 24) to 395.88, marking an increase of 52.77.
- For Revenue From Operations / Share (Rs.), as of Mar 25, the value is 457.88. It has increased from 424.23 (Mar 24) to 457.88, marking an increase of 33.65.
- For PBDIT / Share (Rs.), as of Mar 25, the value is 77.88. This value is within the healthy range. It has increased from 61.36 (Mar 24) to 77.88, marking an increase of 16.52.
- For PBIT / Share (Rs.), as of Mar 25, the value is 54.55. This value is within the healthy range. It has increased from 37.19 (Mar 24) to 54.55, marking an increase of 17.36.
- For PBT / Share (Rs.), as of Mar 25, the value is 62.09. This value is within the healthy range. It has increased from 9.27 (Mar 24) to 62.09, marking an increase of 52.82.
- For Net Profit / Share (Rs.), as of Mar 25, the value is 52.96. This value is within the healthy range. It has increased from 3.08 (Mar 24) to 52.96, marking an increase of 49.88.
- For NP After MI And SOA / Share (Rs.), as of Mar 25, the value is 53.13. This value is within the healthy range. It has increased from 4.88 (Mar 24) to 53.13, marking an increase of 48.25.
- For PBDIT Margin (%), as of Mar 25, the value is 17.00. This value is within the healthy range. It has increased from 14.46 (Mar 24) to 17.00, marking an increase of 2.54.
- For PBIT Margin (%), as of Mar 25, the value is 11.91. This value is within the healthy range. It has increased from 8.76 (Mar 24) to 11.91, marking an increase of 3.15.
- For PBT Margin (%), as of Mar 25, the value is 13.56. This value is within the healthy range. It has increased from 2.18 (Mar 24) to 13.56, marking an increase of 11.38.
- For Net Profit Margin (%), as of Mar 25, the value is 11.56. This value exceeds the healthy maximum of 10. It has increased from 0.72 (Mar 24) to 11.56, marking an increase of 10.84.
- For NP After MI And SOA Margin (%), as of Mar 25, the value is 11.60. This value is within the healthy range. It has increased from 1.15 (Mar 24) to 11.60, marking an increase of 10.45.
- For Return on Networth / Equity (%), as of Mar 25, the value is 13.41. This value is below the healthy minimum of 15. It has increased from 1.41 (Mar 24) to 13.41, marking an increase of 12.00.
- For Return on Capital Employeed (%), as of Mar 25, the value is 8.13. This value is below the healthy minimum of 10. It has increased from 6.08 (Mar 24) to 8.13, marking an increase of 2.05.
- For Return On Assets (%), as of Mar 25, the value is 6.58. This value is within the healthy range. It has increased from 0.66 (Mar 24) to 6.58, marking an increase of 5.92.
- For Long Term Debt / Equity (X), as of Mar 25, the value is 0.34. This value is within the healthy range. It has decreased from 0.58 (Mar 24) to 0.34, marking a decrease of 0.24.
- For Total Debt / Equity (X), as of Mar 25, the value is 0.38. This value is within the healthy range. It has decreased from 0.62 (Mar 24) to 0.38, marking a decrease of 0.24.
- For Asset Turnover Ratio (%), as of Mar 25, the value is 0.59. There is no change compared to the previous period (Mar 24) which recorded 0.59.
- For Current Ratio (X), as of Mar 25, the value is 1.65. This value is within the healthy range. It has decreased from 2.05 (Mar 24) to 1.65, marking a decrease of 0.40.
- For Quick Ratio (X), as of Mar 25, the value is 1.13. This value is within the healthy range. It has decreased from 1.37 (Mar 24) to 1.13, marking a decrease of 0.24.
- For Inventory Turnover Ratio (X), as of Mar 25, the value is 5.98. This value is within the healthy range. It has increased from 1.36 (Mar 24) to 5.98, marking an increase of 4.62.
- For Dividend Payout Ratio (NP) (%), as of Mar 25, the value is 9.48. This value is below the healthy minimum of 20. It has decreased from 103.24 (Mar 24) to 9.48, marking a decrease of 93.76.
- For Dividend Payout Ratio (CP) (%), as of Mar 25, the value is 6.58. This value is below the healthy minimum of 20. It has decreased from 17.34 (Mar 24) to 6.58, marking a decrease of 10.76.
- For Earning Retention Ratio (%), as of Mar 25, the value is 90.52. This value exceeds the healthy maximum of 70. It has increased from -3.24 (Mar 24) to 90.52, marking an increase of 93.76.
- For Cash Earning Retention Ratio (%), as of Mar 25, the value is 93.42. This value exceeds the healthy maximum of 70. It has increased from 82.66 (Mar 24) to 93.42, marking an increase of 10.76.
- For Interest Coverage Ratio (X), as of Mar 25, the value is 5.12. This value is within the healthy range. It has increased from 3.56 (Mar 24) to 5.12, marking an increase of 1.56.
- For Interest Coverage Ratio (Post Tax) (X), as of Mar 25, the value is 2.99. This value is below the healthy minimum of 3. It has increased from 1.80 (Mar 24) to 2.99, marking an increase of 1.19.
- For Enterprise Value (Cr.), as of Mar 25, the value is 15,436.46. It has increased from 11,426.80 (Mar 24) to 15,436.46, marking an increase of 4,009.66.
- For EV / Net Operating Revenue (X), as of Mar 25, the value is 2.13. This value is within the healthy range. It has increased from 1.70 (Mar 24) to 2.13, marking an increase of 0.43.
- For EV / EBITDA (X), as of Mar 25, the value is 12.54. This value is within the healthy range. It has increased from 11.79 (Mar 24) to 12.54, marking an increase of 0.75.
- For MarketCap / Net Operating Revenue (X), as of Mar 25, the value is 1.95. This value is within the healthy range. It has increased from 1.34 (Mar 24) to 1.95, marking an increase of 0.61.
- For Retention Ratios (%), as of Mar 25, the value is 90.51. This value exceeds the healthy maximum of 70. It has increased from -3.24 (Mar 24) to 90.51, marking an increase of 93.75.
- For Price / BV (X), as of Mar 25, the value is 2.25. This value is within the healthy range. It has increased from 1.65 (Mar 24) to 2.25, marking an increase of 0.60.
- For Price / Net Operating Revenue (X), as of Mar 25, the value is 1.95. This value is within the healthy range. It has increased from 1.34 (Mar 24) to 1.95, marking an increase of 0.61.
- For EarningsYield, as of Mar 25, the value is 0.05. This value is below the healthy minimum of 5. It has increased from 0.01 (Mar 24) to 0.05, marking an increase of 0.04.
Overall, while many metrics show healthy performance, any figures highlighted in red or significant downward trends warrant further investigation.
Strength and Weakness
| Strength | Weakness |
|---|---|
|
|
Stock Analysis
- Considering all of the following key financial indicators, prospective investors are encouraged to conduct thorough research and seek professional guidance before considering any investment in Jubilant Pharmova Ltd:
- Net Profit Margin: 11.56%
- Net Profit Margin: This metric indicates the percentage of profit a company makes from its total revenue. A higher net profit margin is generally desirable as it reflects better profitability.
- ROCE: 8.13% (Industry Average ROCE: 16.29%)
- ROCE (Return on Capital Employed): ROCE measures a company's profitability and the efficiency with which its capital is employed. A higher ROCE indicates efficient use of capital.
- ROE%: 13.41% (Industry Average ROE: 15.2%)
- ROE (Return on Equity): ROE measures a company's profitability relative to shareholders' equity. A higher ROE indicates efficient use of shareholders' funds.
- Interest Coverage Ratio (Post Tax): 2.99
- Interest Coverage Ratio: The interest coverage ratio measures a company's ability to cover its interest payments on outstanding debt. A ratio greater than 2 is generally considered healthy as it indicates the company can meet its interest obligations comfortably.
- Quick Ratio: 1.13
- Quick Ratio: The quick ratio assesses a company's ability to cover its short-term liabilities with its most liquid assets. A ratio higher than 1 suggests the company can meet its short-term obligations without relying heavily on inventory.
- Stock P/E: 34.4 (Industry average Stock P/E: 53.08)
- Stock P/E (Price-to-Earnings) Ratio: The P/E ratio compares a company's current share price to its earnings per share. A lower P/E ratio relative to industry peers or historical values may indicate that the stock is undervalued.
- Total Debt / Equity: 0.38
- Total Debt / Equity: This ratio measures a company's financial leverage by comparing its total debt to its total equity. A lower ratio indicates lower financial risk and greater financial stability.
Stock Rating: - Net Profit Margin: 11.56%
About the Company - Qualitative Analysis
| INDUSTRY | ADDRESS | CONTACT |
|---|---|---|
| Pharmaceuticals | Bhartiagram, Amroha District Uttar Pradesh 244223 | Contact not found |
| Management | |
|---|---|
| Name | Position Held |
| Mr. Shyam S Bhartia | Chairman |
| Mr. Hari S Bhartia | Co-Chairman |
| Mr. Priyavrat Bhartia | Managing Director |
| Mr. Arjun Shanker Bhartia | Joint Managing Director |
| Mr. Arvind Chokhany | WholeTime Director & Group CFO |
| Dr. Ramakrishnan Arul | Whole Time Director |
| Dr. Harsh Mahajan | Independent Director |
| Mr. Arun Seth | Independent Director |
| Mr. Vivek Mehra | Independent Director |
| Ms. Shivpriya Nanda | Independent Director |
| Mr. Shirish G Belapure | Independent Director |
| Mr. Sushil Kumar Roongta | Independent Director |
FAQ
What is the intrinsic value of Jubilant Pharmova Ltd?
Jubilant Pharmova Ltd's intrinsic value (as of 24 December 2025) is 1093.06 which is 1.77% higher the current market price of 1,074.00, indicating undervalued. Calculated using the PE ratio method, this valuation considers the company's 17,110 Cr. market cap, FY2025-2026 high/low of 1,250/802, reserves of ₹6,576 Cr, and liabilities of 13,521 Cr.
What is the Market Cap of Jubilant Pharmova Ltd?
The Market Cap of Jubilant Pharmova Ltd is 17,110 Cr..
What is the current Stock Price of Jubilant Pharmova Ltd as on 24 December 2025?
The current stock price of Jubilant Pharmova Ltd as on 24 December 2025 is 1,074.
What is the High / Low of Jubilant Pharmova Ltd stocks in FY 2025-2026?
In FY 2025-2026, the High / Low of Jubilant Pharmova Ltd stocks is 1,250/802.
What is the Stock P/E of Jubilant Pharmova Ltd?
The Stock P/E of Jubilant Pharmova Ltd is 34.4.
What is the Book Value of Jubilant Pharmova Ltd?
The Book Value of Jubilant Pharmova Ltd is 414.
What is the Dividend Yield of Jubilant Pharmova Ltd?
The Dividend Yield of Jubilant Pharmova Ltd is 0.46 %.
What is the ROCE of Jubilant Pharmova Ltd?
The ROCE of Jubilant Pharmova Ltd is 9.54 %.
What is the ROE of Jubilant Pharmova Ltd?
The ROE of Jubilant Pharmova Ltd is 9.55 %.
What is the Face Value of Jubilant Pharmova Ltd?
The Face Value of Jubilant Pharmova Ltd is 1.00.